Cancer Treatment Eased by Eric Lefkofsky

Cancer is currently the most dangerous disease. Eric Lefkofsky co-founded a company called Tempus, mainly focused on using genomic sequencing to help customize cancer treatments. Recently, the Chicago based company, Tempus, announced that it raised $ 70 million from New Enterprise Associates and Revolution Growth in its series C funding. This financing will sum up the total amount raised since Tempus was established in 2015 to $ 130 million and more information click here.

Eric Lefkofsky who serves as the CEO and his business partner, Brad Keywell take part significantly in every fundraising round for Tempus. Last year, Eric told Crain’s Chicago that he is willing to invest up to $ 100 million in the business. Investors New Enterprise Associates and Revolution Growth have also funded companies like stock trading app Robinhood and salad restaurant Sweetgreen respectively among others and Eric on Facebook.

After many years in the tech industry, Eric Lefkofsky ventured into the healthcare when a loved one was diagnosed with breast cancer. During treatment, Eric realized there is short of technology on how data collection was conducted. Tempus was then established, which has created platforms of technology that compile genomic and clinical data from cancer patients making it easier for doctors to personalize the treatment.

Datasets have been small and disorganized but with Tempus massive amount of molecular and clinical data are amassed benefiting the patient. Last year Tempus announced partnerships withDuke University School of medicine, the Mayo Clinic, Cleveland Clinic and many others. Tempus looks forward to building the world’s most extensive library of clinical and molecular data to customize and improve cancer treatment and Eric’s lacrosse camp.

Eric Lefkofsky was born in Southfield, Michigan but most of his adult life was in Chicago. He graduated with honors from the University of Michigan. Later, he attained his Juris Doctor from the University of Michigan, Law School. He also serves as the chairman of Groupon, and co-founder of Uptake Technologies.

Together with Brad Keywell, they have established several companies like VC fund Lightbank. Eric has committed staff members at Tempus who work hard to provide care to cancer patients. Eric and his wife established Lefkofsky Foundation to support organizations globally. Caring for patients and loved ones is the motive of Tempus and

Mikhail Blagosklonny Provides a Comprehensive Understanding of Oncology

Mikhail Blagosklonny is a renowned scientist and professor of Oncology in New York, in the USA. Currently, Mikhail Blagosklonny works at Roswell Park Cancer Institute. He is an expert in different fields, including cancer and aging. Therefore, for several years, he has been helping cancer patients and aged people to cope effectively with life. Blagosklonny earned an MD in Internal Medicine at the prominent First Pavlov State Medical University.

Additionally, at the same medical university, Mikhail acquired his Ph.D. in Experimental Medicine and Cardiology. Therefore, he is an experienced professional who is always ready to offer excellent help to his clients. He understands the essence of respecting other people, including his clients because he believes that his services are to assist them by offering solutions to the problems that seem impossible. As an expert in the field of oncology, Mikhail has helped hundreds of patients affected by tumors. He helps people to understand the illness at different stages. Also, Mikhail performs the diagnosis to the development of tumors to enhance the treatment process. He has been offering prevention tips to the aged and other people in the USA and other areas in the world, through his official online platform. Read more on

Due to his notable expertise, in 2002, Mikhail Blagosklonny became an associate professor in the field of medicine at the New York Medical College. Later on, Mikhail Blagosklonny served as a senior scientist at Ordway Research Institute. At the institution, he portrayed exceptional professionalism in his service delivery. He was able to work effectively with other team members. He formed solid teams to achieve short-term and long-term objectives of the firm.

After working as a senior scientist for several years, he gained more skills and experience. Additionally, he was able to deal with challenges in different situations and relate with people professionally. In 2009, he became a professor of oncology at Roswell Park Cancer Institute located in New York in the United States of America. At the institution, he has been performing several research studies in different fields, including the research about cancer therapies, anti-aging drugs, cancer cells and many others. He targets to help the old individuals who live with cancer so that the unaffected body cells do not get damaged by the deadly disease.

Mikhail’s other research areas include the following: anticancer therapeutics, tumor suppressors, mitosis, signal transduction, and apoptosis, among others. Additionally, he is an editor-in-chief of Oncotarget and Cell Cycle and Cancer, biology, and therapy associate editor. Therefore, he knows varieties of things that affect the aged and the cancer patients. He is the person who proposed the usage of Rapamycin in the treatment process of cancer. Therefore, he believes that it is possible to control cancer and the aging process. His principal objective is to fulfill his vision of having a disease-free community in the future. View his LinkedIn profile

Conclusively, Blagosklonny is a renowned author of different aspects, including aging hyperfunction theory. He has an exceptional interest in oncology. That is the reason why he continues to perform extensive researches every day to look for long-term solutions to these conditions. There are hundreds of research articles, reviews, and books published under Mikhail’s name.

Rutgers Cancer Institute Establishes Omar Boraie Chair

In a bid to propel research on precision medicine, the Rutgers Cancer Institute ( has established the Omar Boraie Chair in Genomic Science.

Genomic science is an important part of the higher education, and its advancement is crucial. That is the reason why the Institute established the 18 chair challenge campaign to raise funds for the advancement of the discipline.

Omar Boraie was one of the 18 chairs that made a pledge for supporting the Institute. He pledged $1.5 million towards the campaign. That is what has led to the establishment of a chair under his name. Dr. Shridar Ganesan, MD, associate director for the translational science have been named to this chair. He is also the principal investigator of the precision medicine.

It is a new medical approach that will analyze and also treat the cancer cells on a genetic level. This will help the medical personnel to prescribe individualized therapies.

The former president of the United States Barack Obama announced the launch of a National Precision Medicine Initiative during one of his State of the Nation address. This initiative will be focused on finding a cure for cancer and other terminal diseases.

There are different centers that are using the next-generation treatment. However, it is only Rutgers Cancer Institute that is dealing with genomic science and precision medicine. Genomic science has played an important role in the establishing treatments for the rare cancer tumors. Precision medicine will help in the classification of the cancer tumors in subgroups with similar characteristics.

Boraie said that he is hopeful that his pledge will make a significant impact in the Institute. He supports the research being done to establish a therapy treatment for the patients who are no longer responding to medication.

The Rutgers Cancer Institute is the first State-owned National Cancer Institute which is Comprehensive Cancer Center. The Institute is dedicated to improving the treatment of the different cancer tumors. The State University of New Jersey and the Cancer Institute of New Jersey are part of the Institute.

The scientists in the institute bring their research into reality by using the translational approach to their research.

This are article first published on